These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Intranasal Lipid Particulate Drug Delivery Systems: An Update on Clinical Challenges and Biodistribution Studies of Cerebroactive Drugs in Alzheimer's disease. Arora D; Bhatt S; Kumar M; Vattikonda HDC; Taneja Y; Jain V; Joshi V; Gali CC Curr Pharm Des; 2020; 26(27):3281-3299. PubMed ID: 32228421 [TBL] [Abstract][Full Text] [Related]
4. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. Agrawal M; Saraf S; Saraf S; Antimisiaris SG; Chougule MB; Shoyele SA; Alexander A J Control Release; 2018 Jul; 281():139-177. PubMed ID: 29772289 [TBL] [Abstract][Full Text] [Related]
5. Lipid nanoparticles for intranasal administration: application to nose-to-brain delivery. Battaglia L; Panciani PP; Muntoni E; Capucchio MT; Biasibetti E; De Bonis P; Mioletti S; Fontanella M; Swaminathan S Expert Opin Drug Deliv; 2018 Apr; 15(4):369-378. PubMed ID: 29338427 [TBL] [Abstract][Full Text] [Related]
6. Strategic nanocarriers to control neurodegenerative disorders: Concept, challenges, and future perspective. Ashique S; Afzal O; Yasmin S; Hussain A; Altamimi MA; Webster TJ; Altamimi ASA Int J Pharm; 2023 Feb; 633():122614. PubMed ID: 36646255 [TBL] [Abstract][Full Text] [Related]
7. Insulin Delivery to the Brain via the Nasal Route: Unraveling the Potential for Alzheimer's Disease Therapy. Wong CYJ; Baldelli A; Hoyos CM; Tietz O; Ong HX; Traini D Drug Deliv Transl Res; 2024 Jul; 14(7):1776-1793. PubMed ID: 38441832 [TBL] [Abstract][Full Text] [Related]
8. Nanotechnological Advances for Nose to Brain Delivery of Therapeutics to Improve the Parkinson Therapy. Khatri DK; Preeti K; Tonape S; Bhattacharjee S; Patel M; Shah S; Singh PK; Srivastava S; Gugulothu D; Vora L; Singh SB Curr Neuropharmacol; 2023; 21(3):493-516. PubMed ID: 35524671 [TBL] [Abstract][Full Text] [Related]
9. Intranasal nanotherapeutics for brain targeting and clinical studies in Parkinson's disease. Saha P; Kathuria H; Pandey MM J Control Release; 2023 Jun; 358():293-318. PubMed ID: 37061193 [TBL] [Abstract][Full Text] [Related]
10. Convolutions in the rendition of nose to brain therapeutics from bench to bedside: Feats & fallacies. Goel H; Kalra V; Verma SK; Dubey SK; Tiwary AK J Control Release; 2022 Jan; 341():782-811. PubMed ID: 34906605 [TBL] [Abstract][Full Text] [Related]
11. Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders. Islam SU; Shehzad A; Ahmed MB; Lee YS Molecules; 2020 Apr; 25(8):. PubMed ID: 32326318 [TBL] [Abstract][Full Text] [Related]
12. Current Overview on the Use of Nanosized Drug Delivery Systems in the Treatment of Neurodegenerative Diseases. Ozceylan O; Sezgin-Bayindir Z ACS Omega; 2024 Aug; 9(33):35223-35242. PubMed ID: 39184484 [TBL] [Abstract][Full Text] [Related]
13. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases. Teixeira MI; Lopes CM; Amaral MH; Costa PC Eur J Pharm Biopharm; 2020 Apr; 149():192-217. PubMed ID: 31982574 [TBL] [Abstract][Full Text] [Related]
14. Updated Progress of Nanocarrier-Based Intranasal Drug Delivery Systems for Treatment of Brain Diseases. Fan Y; Chen M; Zhang J; Maincent P; Xia X; Wu W Crit Rev Ther Drug Carrier Syst; 2018; 35(5):433-467. PubMed ID: 30317945 [TBL] [Abstract][Full Text] [Related]
15. Lipid Nanoparticles for Nasal/Intranasal Drug Delivery. Cunha S; Amaral MH; Lobo JMS; Silva AC Crit Rev Ther Drug Carrier Syst; 2017; 34(3):257-282. PubMed ID: 28845761 [TBL] [Abstract][Full Text] [Related]
16. Strategies for intranasal delivery of therapeutics for the prevention and treatment of neuroAIDS. Hanson LR; Frey WH J Neuroimmune Pharmacol; 2007 Mar; 2(1):81-6. PubMed ID: 18040829 [TBL] [Abstract][Full Text] [Related]
17. Micro- and Nanosized Carriers for Nose-to-Brain Drug Delivery in Neurodegenerative Disorders. Boyuklieva R; Pilicheva B Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35885011 [TBL] [Abstract][Full Text] [Related]
18. Stimuli-responsive In situ gelling system for nose-to-brain drug delivery. Agrawal M; Saraf S; Saraf S; Dubey SK; Puri A; Gupta U; Kesharwani P; Ravichandiran V; Kumar P; Naidu VGM; Murty US; Ajazuddin ; Alexander A J Control Release; 2020 Nov; 327():235-265. PubMed ID: 32739524 [TBL] [Abstract][Full Text] [Related]
19. Navigating into the Paradigm of Nose-to-brain Delivery of Nanotherapeutics and their Repurposing as Nanotheranostics for Neurodegenerative Diseases. Ali A; A Emad N; Sultana N; Waheed A; Aqil M; Sultana Y; Mujeeb M CNS Neurol Disord Drug Targets; 2024 Oct; ():. PubMed ID: 39400020 [TBL] [Abstract][Full Text] [Related]
20. Drug Delivery and Targeting to the Brain Through Nasal Route: Mechanisms, Applications and Challenges. Kashyap K; Shukla R Curr Drug Deliv; 2019; 16(10):887-901. PubMed ID: 31660815 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]